Basal Cell Carcinoma Clinical Presentation
- Author: Robert S Bader, MD; Chief Editor: William D James, MD more...
Patients presenting with basal cell carcinoma (BCC) often report a slowly enlarging lesion that does not heal and that bleeds when traumatized. As tumors most commonly occur on the face, patients often give a history of an acne bump that occasionally bleeds.
People who sunburn are more likely to develop skin cancer than those who do not; however, sunlight damages the skin with or without sunburn. Consider BCC in any patient with a history of a sore or skin anomaly that does not heal within 3-4 weeks and occurs on sun-exposed skin, especially if it is dimpled in the middle. These tumors may take many months or years to reach even 1 cm in diameter.
Patients often have a history of chronic sun exposure, including recreational sun exposure (eg, sunbathing, outdoor sports, fishing, boating) and occupational sun exposure (eg, farming, construction).
History of any prior treatment to the index tumor should be elicited, as well as history of any prior non-melanoma skin cancer. In patients with recurrent tumors, deeper invasion should be expected. Recurrence following radiation therapy is often biologically more aggressive.
Occasionally, patients have a history of exposure to ionizing radiation. X-ray therapy for acne was commonly used until 1950. Though not common, patients have a history of arsenic intake; arsenic is found in well water in some parts of the United States.
Characteristic features of BCC tumors include the following:
Waxy papules with central depression
Erosion or ulceration, often central
Bleeding, especially when traumatized
Rolled (raised) border
Telangiectases over the surface
Slow growing (0.5 cm in 1-2 y)
Basal cell carcinoma occurs mostly on the face, head (scalp included), neck, and hands. It rarely develops on the palms and soles. BCC usually appears as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. BCCs may have one or more visible and irregular blood vessels, an ulcerative area in the center that often is pigmented, and black-blue or brown areas. Large BCCs may have oozing or crusted areas. The lesion grows slowly, is not painful, and does not itch.
Periocular tumors most commonly involve the lower eyelid (48.9-72.1%), followed by the medial canthus (25-30%), the upper eyelid (15%), and the lateral canthus (5%). Examples are shown in the images below.
Though a literature review showed all authors agreed that periocular BCC most commonly occurs in the lower eyelid, the remaining anatomical locations and the incidence of occurrence differ among the studies.
Younger patients (< 40 y) may have a lower prevalence of BCC on the head and neck and a higher prevalence on the trunk, with greater tendency to superficial BCC, than in older patients. Childhood BCC is exceedingly rare in the absence of other underlying conditions. Only 107 cases of de novo childhood BCC have been reported in the literature, but the majority (90%) occurred on the head and neck, and aggressive subtypes were observed in 20% of the total cases.
Clinical presentation of BCC varies by type. Physical examination of the skin aids in determination of tumor extent, subtype, and involvement of important cosmetic and functional structures. Matted BCCs may indicate deeper tumor invasion and involvement of deeper underlying structures. In patients with recurrent or deeply infiltrative tumors, involvement of the facial nerve or branches of the trigeminal nerve should be investigated. Facial nerve function can be monitored by comparing facial symmetry during voluntary facial movements with that at rest. Sensory nerve function can be tested and compared to the nonaffected side by means of light touch and pinprick. Orbital invasion can cause diplopia, proptosis, and ophthalmoplegia. Any limitation in ocular movements and/or diplopia should be tested.
BCC seldom causes regional or distant metastasis, with the exception of the metatypical basosquamous type. To evaluate for lymph node metastasis, particular attention should be taken to examine the parotid posterior auricular, suboccipital, and upper cervical groups of lymph nodes.
Several different clinicopathologic types of BCC exist, each with distinct biologic behavior:
Nodular - Cystic, pigmented, keratotic
Nodular basal cell carcinoma
Nodular basal cell carcinoma is the most common type of basal cell carcinoma and usually presents as a round, pearly, flesh-colored papule with telangiectases. More than 60% of BCCs belong to this subtype. As it enlarges, it frequently ulcerates centrally, leaving a raised, pearly border with telangiectases, which aids in making the diagnosis. Fine vessels may bleed, resulting in hemosiderin deposition.
The tumor may present as a cyst, which can be mistaken for inclusion cysts of the eyelid. Cystic BCC is an uncommon variant of nodular BCC and is often clinically indistinguishable from nodular basal cell carcinoma, although it might have a polypoid, cystic appearance. Typically, a bluish-gray cystlike lesion is observed. The cystic center of the tumor is filled with clear mucin that has a gelatinlike consistency. Often, one can see the typical features of a nodular basal cell carcinoma in addition to the cystic features.
Most tumors are observed on the face, although the trunk and extremities also are affected. See the images below.
Pigmented basal cell carcinoma (see the images below) is an uncommon variant of nodular basal cell carcinoma that usually has brown-black macules in some areas or affecting nearly the entire tumor, occasionally making it difficult to differentiate from melanoma.
Typically, some areas of these tumors do not retain pigment, and pearly, raised borders with telangiectases that are typical of a nodular basal cell carcinoma can be observed. This aids clinically in differentiating this tumor from a malignant melanoma. See the images below.
Keratotic BCC is a variant of nodular BCC and is usually clinically indistinguishable from nodular BCC histologically.
Infiltrative basal cell carcinoma
With this variant of BCC, tumor infiltrates the dermis in thin strands between collagen fibers, making tumor margins less clinically apparent. Mohs micrographic surgery is the treatment of choice for infiltrative basal cell carcinoma. Because of its growth pattern, electrodesiccation and curettage has a significantly higher recurrence rate when used to treat infiltrative BCC compared to the treatment of nodular BCC; other treatment methods should be sought.
Micronodular basal cell carcinoma
This aggressive BCC subtype has the typical BCC distribution. It is not prone to ulceration, it may appear yellow-white when stretched, and it is firm to the touch. It may have a seemingly well-defined border.
Morpheaform (sclerosing) basal cell carcinoma
Morpheaform basal cell carcinoma is an uncommon variant in which tumor cells induce a proliferation of fibroblasts within the dermis and an increased collagen deposition (sclerosis) that clinically resembles a scar. This form accounts for 10% of lesions.
Such lesions appear as flat or slightly depressed, fibrotic, and firm. The tumor appears as a white or yellow, waxy, sclerotic plaque that rarely ulcerates. The morpheaform (sclerosing) type of basal cell carcinoma is often the most difficult type to diagnose, as it bears little resemblance to the typical nodular BCC.
Because the tumor infiltrates in thin strands between collagen fibers, treatment is difficult because the clinical margins are difficult to distinguish from normal, uninvolved skin. Mohs micrographic surgery is the treatment of choice for morpheaform basal cell carcinoma because recurrence is more likely with other treatment modalities.
Ulceration, bleeding, and crusting are uncommon and these tumors are commonly mistaken for scar tissue (see the image below).
Superficial basal cell carcinoma
Superficial basal cell carcinomas are seen mostly on the upper trunk or shoulders. This type of BCC grows slowly, has minimal tendency to be invasive, and appears clinically as an erythematous, well-circumscribed patch or plaque, often with a whitish scale. Occasionally, minute eschars may appear within the patch or plaque. The tumor often appears multicentric, with areas of clinically normal skin intervening among clinically involved areas.
A threadlike border is common but not always present. Erosion is less common in superficial BCC than in nodular BCC, although pinpoint areas of hemorrhage or eschar may be present. The papules may mimic psoriasis or eczema, but they are slowly progressive and are not prone to fluctuate in appearance. Numerous superficial BCCs may indicate arsenic exposure. See the images below.
Gorlin syndrome or basal cell nevus syndrome
Basal cell carcinoma (BCC) is also a feature of basal cell nevus syndrome (ie, Gorlin syndrome), an autosomal dominant inherited condition. The lesions in these patients cannot be distinguished histologically from ordinary BCCs. The gene responsible for this syndrome is located on arm 9q, and chromosome abnormalities develop in some patients. The number of BCCs in patients with this syndrome may number from one to hundreds. Multiple BCCs begin to appear after puberty on the face, trunk, and extremities. In many cases, the tumors are highly invasive and may involve areas around the eyes and nose.
Other features associated with Gorlin syndrome (fortunately, uncommon) include the following :
Congenital agenesis of the corpus callosum and medulloblastoma
Odontogenic jaw cysts
Bifid ribs and pectus excavatum
Absent or undescended testes
Mesenteric lymphatic cysts
Palmar and plantar pits
Ectopic calcification (particularly of the falx cerebri)
Ocular and skeletal abnormalities (eg, hypertelorism, shortening of the fourth and fifth metacarpals)
Other basal cell carcinomas
Other types of basal cell carcinoma include the following:
Kumar N, Saxena YK. Two cases of rare presentation of basal cell and squamous cell carcinoma on the hand. Indian J Dermatol Venereol Leprol. 2002 Nov-Dec. 68(6):349-51. [Medline].
Barry J, Oon SF, Watson R, Barnes L. The management of basal cell carcinomas. Ir Med J. 2006 Jun. 99(6):179-81. [Medline].
[Guideline] Dandurand M, Petit T, Martel P, Guillot B. Management of basal cell carcinoma in adults Clinical practice guidelines. Eur J Dermatol. 2006 Jul-Aug. 16(4):394-401. [Medline].
[Guideline] Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014 May-Jun. 24 (3):312-29. [Medline].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer, Version 1.2015. NCCN. Available at http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed: July 29, 2015.
Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009 Oct. 119(10):1994-9. [Medline].
Erba P, Farhadi J, Wettstein R, Arnold A, Harr T, Pierer G. Morphoeic basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg. 2007. 41(4):184-8. [Medline].
Fresini A, Rossiello L, Severino BU, Del Prete M, Satriano RA. Giant basal cell carcinoma. Skinmed. 2007 Jul-Aug. 6(4):204-5. [Medline].
Shindel AW, Mann MW, Lev RY, et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol. 2007 Nov. 178(5):1980-5. [Medline].
Mulvany NJ, Allen DG. Differentiated intraepithelial neoplasia of the vulva. Int J Gynecol Pathol. 2008 Jan. 27(1):125-35. [Medline].
Cabrera HN, Cuda G, Lopez M, Costa JA. [Basal cell epithelioma of the vulva in chronic endemic regional arsenic poisoning]. Med Cutan Ibero Lat Am. 1984. 12(2):81-5. [Medline].
Newman JC, Leffell DJ. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg. 2007 Aug. 33(8):957-64; discussion 965. [Medline].
Cabrera HN, Gomez ML. Skin cancer induced by arsenic in the water. J Cutan Med Surg. 2003 Mar-Apr. 7(2):106-11. [Medline].
Romao-Correa RF, Maria DA, Soma M, et al. Nucleolar organizer region staining patterns in paraffin-embedded tissue cells from human skin cancers. J Cutan Pathol. 2005 May. 32(5):323-8. [Medline].
Ozyazgan I, Kontas O. Previous injuries or scars as risk factors for the development of basal cell carcinoma. Scand J Plast Reconstr Surg Hand Surg. 2004. 38(1):11-5. [Medline].
Mohanty P, Mohanty L, Devi BP. Multiple cutaneous malignancies in xeroderma pigmentosum. Indian J Dermatol Venereol Leprol. 2001 Mar-Apr. 67(2):96-7. [Medline].
Keyhani K, Ashenhurst M, Oryschak A. Periocular basal cell carcinoma arising in a site of previous trauma. Can J Ophthalmol. 2007 Jun. 42(3):467-8. [Medline].
Aldara cream 5% (imiquimod) [package insert]. Graceway Pharmaceuticals. 2007.
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May. 50(5):722-33. [Medline].
Sapijaszko MJ. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett. 2005 Jul-Aug. 10(6):2-5. [Medline].
Micali M, Nasca MR, Musumeci ML. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream. Int J Tissue React. 2005. 27(3):111-4. [Medline].
Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003 Nov. 149 Suppl 66:5-8. [Medline].
Wuest M, Dummer R, Urosevic M. Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. Arch Dermatol Res. 2007 Dec. 299(10):493-8. [Medline].
Efudex (fluorouracil) [package insert]. Valeant Pharmaceuticals. 2005.
Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001 Apr. 10(7):757-62. [Medline].
Wicking C, McGlinn E. The role of hedgehog signalling in tumorigenesis. Cancer Lett. 2001 Nov 8. 173(1):1-7. [Medline].
National Center for Biotechnical Information. Tumor Protein p53; TP53. Available at http://www.ncbi.nlm.nih.gov/omim/191170. Accessed: November 7, 2007.
Young LC, Listgarten J, Trotter MJ, Andrew SE, Tron VA. Evidence that dysregulated DNA mismatch repair characterizes human nonmelanoma skin cancer. Br J Dermatol. 2008 Jan. 158(1):59-69. [Medline].
Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol. 2005 Mar. 124(3):505-13. [Medline].
Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004 Aug-Dec. 23(3-4):389-402. [Medline].
Centers for Disease Control and Prevention (CDC). Sunburn prevalence among adults--United States, 1999, 2003, and 2004. MMWR Morb Mortal Wkly Rep. 2007 Jun 1. 56(21):524-8. [Medline].
Cohen MM Jr. Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses. Int J Oral Maxillofac Surg. 1999 Jun. 28(3):216-23. [Medline].
Klein RD, Dykas DJ, Bale AE. Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory. Genet Med. 2005 Nov-Dec. 7(9):611-9. [Medline].
Karagas MR. Occurrence of cutaneous basal cell and squamous cell malignancies among those with a prior history of skin cancer. The Skin Cancer Prevention Study Group. J Invest Dermatol. 1994 Jun. 102(6):10S-13S. [Medline].
Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol. 1981. 61(6):497-503. [Medline].
Heal C, Buettner P, Browning S. Risk factors for wound infection after minor surgery in general practice. Med J Aust. 2006 Sep 4. 185(5):255-8. [Medline].
What are the key statistics about basal and squamous cell skin cancers?. American Cancer Society. Available at http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-key-statistics. April 30, 2015; Accessed: August 31, 2015.
Marks R, Jolley D, Dorevitch AP, Selwood TS. The incidence of non-melanocytic skin cancers in an Australian population: results of a five-year prospective study. Med J Aust. 1989 May 1. 150(9):475-8. [Medline].
Brasseur R, Lagesse Ch. [Contribution of psychometry of clinical evaluation of the therapeutic effect of "Solcoseryl" in states of intellectual weakness connected with chronic cerebral circulatory insufficiency (author's transl)]. Schweiz Rundsch Med Prax. 1977 Mar 8. 66(10):312-7. [Medline].
Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999 Apr. 106(4):746-50. [Medline].
Leffell DJ, Headington JT, Wong DS, Swanson NA. Aggressive-growth basal cell carcinoma in young adults. Arch Dermatol. 1991 Nov. 127(11):1663-7. [Medline].
Patel MS, Thigpen JT, Vance RB, Elkins SL, Guo M. Basal cell carcinoma with lung metastasis diagnosed by fine-needle aspiration biopsy. South Med J. 1999 Mar. 92(3):321-4. [Medline].
Akinci M, Aslan S, Markoc F, Cetin B, Cetin A. Metastatic basal cell carcinoma. Acta Chir Belg. 2008 Mar-Apr. 108(2):269-72. [Medline].
Mc Loone NM, Tolland J, Walsh M, et al. Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol. Jul 2006. 20(6):698-701.
Pieh S, Kuchar A, Novak P, Kunstfeld R, Nagel G, Steinkogler FJ. Long-term results after surgical basal cell carcinoma excision in the eyelid region. Br J Ophthalmol. 1999 Jan. 83(1):85-8. [Medline]. [Full Text].
Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000 Dec. 136(12):1524-30. [Medline].
Levi F, Randimbison L, Maspoli M, Te VC, La Vecchia C. High incidence of second basal cell skin cancers. Int J Cancer. 2006 Sep 15. 119(6):1505-7. [Medline].
Bruce AJ, Brodland DG. Overview of skin cancer detection and prevention for the primary care physician. Mayo Clin Proc. 2000 May. 75(5):491-500. [Medline].
Betti R, Radaelli G, Mussino F, Menni S, Crosti C. Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference?. Dermatol Surg. 2009 Feb. 35(2):201-6. [Medline].
Griffin JR, Cohen PR, Tschen JA, et al. Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol. 2007 Nov. 57(5 Suppl):S97-102. [Medline].
Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome: unanswered issues. J Lab Clin Med. 1999 Dec. 134(6):551-2. [Medline].
Bernardini FP. Management of malignant and benign eyelid lesions. Curr Opin Ophthalmol. 2006 Oct. 17(5):480-4. [Medline].
Ly JQ. Scintigraphic findings in Gorlin's syndrome. Clin Nucl Med. 2002 Dec. 27(12):913-4. [Medline].
Barton K, Curling OM, Paridaens AD, Hungerford JL. The role of cytology in the diagnosis of periocular basal cell carcinomas. Ophthal Plast Reconstr Surg. 1996 Sep. 12(3):190-4; discussion 195. [Medline].
Orengo IF, Salasche SJ, Fewkes J, Khan J, Thornby J, Rubin F. Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane. J Am Acad Dermatol. 1997 Sep. 37(3 Pt 1):395-7. [Medline].
Cherpelis BS, Turner L, Ladd S, Glass LF, Fenske NA. Innovative 19-minute rapid cytokeratin immunostaining of nonmelanoma skin cancer in Mohs micrographic surgery. Dermatol Surg. 2009 Jul. 35(7):1050-6. [Medline].
Ackerman AB, Gottlieb GJ. Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. Am J Dermatopathol. 2005 Apr. 27(2):155-9. [Medline].
Bowen AR, LeBoit PE. Fibroepithelioma of pinkus is a fenestrated trichoblastoma. Am J Dermatopathol. 2005 Apr. 27(2):149-54. [Medline].
Strauss RM, Edwards S, Stables GI. Pigmented fibroepithelioma of Pinkus. Br J Dermatol. 2004 Jun. 150(6):1208-9. [Medline].
Mannor GE, Wardell K, Wolfley DE, Nilsson GE. Laser Doppler perfusion imaging of eyelid skin. Ophthal Plast Reconstr Surg. 1996 Sep. 12(3):178-85. [Medline].
Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur J Dermatol. 2006 Jul-Aug. 16(4):340-8. [Medline].
Foley P. Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. Australas J Dermatol. 2005 Feb. 46 Suppl 3:S8-10; discussion S23-5. [Medline].
Zimmermann A, Walt H, Haller U, Baas P, Klein SD. Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient. Cancer Chemother Pharmacol. 2003 Feb. 51(2):147-54. [Medline].
Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009 Dec. 145(12):1431-8. [Medline].
Berman B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol. 2008 Jan. 7(1 Suppl 1):s3-6. [Medline].
Brownell I. Nodular basal cell carcinoma: when in doubt, cut it out. J Drugs Dermatol. 2007 Dec. 6(12):1245-6. [Medline].
Farhi D, Dupin N, Palangie A, Carlotti A, Avril MF. Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg. 2007 Oct. 33(10):1207-14. [Medline].
[Guideline] Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012 Oct. 67 (4):531-50. [Medline].
Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol. 1997 Jan. 36(1):72-7. [Medline].
Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986 Sep. 15(3):437-43. [Medline].
Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002 Sep. 47(3):390-8. [Medline].
Garcia-Martin E, Gil-Arribas LM, Idoipe M, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011 Oct. 95(10):1393-6. [Medline].
Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007 Oct. 57(4):616-21. [Medline].
Stockfleth E, Ulrich C, Hauschild A, Lischner S, Meyer T, Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002 Nov-Dec. 12(6):569-72. [Medline].
Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013 Jun. 14(7):647-54. [Medline].
Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004 Jul. 151(1):148-56. [Medline].
Lewis JE. Keloidal basal cell carcinoma. Am J Dermatopathol. 2007 Oct. 29(5):485. [Medline].
Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012 Dec. 67(6):1235-41. [Medline].
Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007 Jan. 56(1):125-43. [Medline].
[Guideline] Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008 Dec. 159(6):1245-66. [Medline].
Calzavara-Pinton PG, Szeimies RM, Ortel B, Zane C. Photodynamic therapy with systemic administration of photosensitizers in dermatology. J Photochem Photobiol B. 1996 Nov. 36(2):225-31. [Medline].
Puccioni M, Santoro N, Giansanti F, et al. Photodynamic therapy using methyl aminolevulinate acid in eyelid basal cell carcinoma: a 5-year follow-up study. Ophthal Plast Reconstr Surg. 2009 Mar-Apr. 25(2):115-8. [Medline].
Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008 Sep. 159(4):864-70. [Medline].
Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007 Sep. 143(9):1131-6. [Medline].
Christensen E, Mork C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol. 2012 Jun. 166(6):1342-8. [Medline].
Kempf RA. Systemic therapy of skin carcinoma. Cancer Treat Res. 1995. 78:137-62. [Medline].
Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17. 361(12):1164-72. [Medline].
Erevedge (vismodegib) Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Accessed: August 31, 2015.
Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun. 16 (6):716-28. [Medline].
Douglas D. Fluorouracil may boost invasive skin cancer risk in some. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/815053. 2013 Nov 26; Accessed: August 31, 2015.
National Center for Biotechnical Information. Bazex Syndrome; BZX. Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/omim/301845 \t _blank. Accessed: November 7, 2007.
Xiong MY, Korgavkar K, Digiovanna JJ, Weinstock MA, Veterans Affairs Topical Tretinoin Chemoprevention Trial Group. Fluorouracil and other predictors of morpheaform basal cell carcinoma among high-risk patients: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. JAMA Dermatol. 2014 Mar. 150(3):332-4. [Medline].